Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2019 Feb;54(2):338-342. doi: 10.1038/s41409-018-0291-5. Epub 2018 Aug 16.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Graft vs Host Disease / etiology
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / complications
  • Leukemia-Lymphoma, Adult T-Cell / pathology
  • Leukemia-Lymphoma, Adult T-Cell / therapy*
  • Male
  • Middle Aged
  • Recurrence
  • T-Lymphocytes, Regulatory / drug effects
  • Time Factors
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • mogamulizumab